Skip to main
BCDA

BioCardia Inc. (BCDA) Stock Forecast & Price Target

BioCardia Inc. (BCDA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioCardia is fully committed to advancing its cell therapy platforms, with a focus on treating heart failure and respiratory diseases, and has received support from the FDA and positive initial trial results. The company plans to continue enrollment in its Phase 3 trials and submit for market approval in Japan, with promising results in a recent study. However, there are potential risks and obstacles that could impact their projected price target.

Bears say

BioCardia is a clinical-stage company with two cell therapy platforms in development for cardiovascular and pulmonary diseases. While their CardiAMP platform has shown potential for treating ischemic heart failure and refractory angina, their allogeneic mesenchymal stem cell therapy platform is still in the early stages of clinical trials. Additionally, the company's financials show a negative net income of $6.87 million in the latest quarter and a low cash balance of $2.34 million. Overall, this coupled with their minimal revenue and high operating expenses suggests a high level of risk and uncertainty for investors.

BioCardia Inc. (BCDA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioCardia Inc. (BCDA) Forecast

Analysts have given BioCardia Inc. (BCDA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioCardia Inc. (BCDA) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioCardia Inc. (BCDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.